Inhibition of the PD‐1/PD‐L1 axis has produced impressive response rates in various malignancies, such as melanoma, renal and non‐small cell lung cancer (Iwai et al, 2002; Topalian et al, 2012; Hamid et al, 2013). The gene discussed is CD274; the disease is melanoma.